Edit |   |
---|---|
Antigenic Specificity | Superoxide Dismutase 1 (SOD1) (Antioxidant Enzyme) |
Clone | [SOD1/2089] |
Host Species | Mouse |
Reactive Species | human. |
Isotype | IgG |
Format | unconjugated |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | Immunohistochemistry (IHC) Formalin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: Cu-Zn superoxide dismutase-1 (SOD-1) is a well-characterized cytosolic scavenger of oxygen free radicals that requires copper and zinc binding to potentiate its enzymatic activity. Enzymatically, SOD-1 facilitates the dismutation of oxygen radicals to hydrogen peroxide and also catalyzes pro-oxidant reactions, which include the peroxidase activity and hydroxyl radical generating activity. SOD-1 is ubiquitously expressed in somatic cells and functions as a homodimer. Defects in the gene encoding SOD-1 have been implicated in the progression of neurological diseases, including amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the loss of spinal motor neurons, Down syndrome and Alzheimers disease. I |
Immunogen | Immunogen: Recombinant full-length human SOD1 protein Cellular Localization: Cytoplasmic |
Other Names | [Amyotrophic lateral sclerosis 1 (ALS1); Cu/Zn SOD; Cu/Zn Superoxide Dismutase; Epididymis Secretory Protein Li 44; Indophenoloxidase A (IPOA); Superoxide Dismutase [Cu-Zn]; Superoxide Dismutase 1 (SOD1)] |
Gene, Accession # | [SOD1], Gene ID: 6647, NCBI: NP_000445.1, UniProt: P00441 |
Catalog # | MBS4380486 |
Price | $190, $340, $340 |
Order / More Info | Superoxide Dismutase 1 (SOD1) (Antioxidant Enzyme) Antibody from MYBIOSOURCE INC. |
Product Specific References | Levanon, D., et al. 1985. Architecture and anatomy of the chromosomal locus in human chromosome 21 encoding the Cu-Zn superoxide dismutase. EMBO J. 4: 77-84. |